This move is archived. Current quotes and coverage live on the stock page.
Follow MBX
Microbix Biosystems Inc. is seeing a significant rise in its stock price, reflecting positive investor sentiment.
Microbix Biosystems Inc. (MBX.TO) is up today, gaining 3.33% to reach a real-time close of CA$0.31. This increase follows recent developments within the company and a slight improvement in its financial performance.
Investor takeaway: Investors might see this rise as a good sign, especially after Microbix's recent quarterly results showed an increase in revenue.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$42.46M
52W high
$0.33
52W low
$0.21
1W change
+5.08%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX · as of Sep 17, 2026
Wall Street analysts forecast MBX stock price to rise 29.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+29.0% Upside
Current Price
C$0.31
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
52.3%
Annualized
90-Day Vol
47.7%
Annualized
Trend (90d)
+6.8%
Annualized drift
90d Mean
C$0.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.31 | C$0.26 – C$0.37 |
| 60 trading days | C$0.32 | C$0.24 – C$0.41 |
| 90 trading days | C$0.32 | C$0.23 – C$0.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Microbix's stock rises 3.33% today
With a market cap of CA$42.6 million, the stock's performance could be influenced by broader market trends and investor sentiment in the biotech industry.
Bull case
The recent 13% revenue growth reported for Q1 2026 suggests that Microbix is on a recovery path, which could attract more investors looking for growth opportunities in the biotech sector.
Bear case
Despite the rise, Microbix still faces challenges, including a negative profit margin and ongoing operational losses, which could dampen investor enthusiasm.
Recent Performance Highlights
Advertisement
Microbix Biosystems Inc. has seen a 3.33% increase in its stock price today, bringing the share price to CA$0.31. This uptick follows the company's announcement of a 13% revenue growth for Q1 2026, which may have boosted investor confidence.
Financial Outlook
While the revenue growth is encouraging, Microbix still operates with a negative profit margin of -38.62%. Investors should consider this alongside the recent positive momentum in stock performance, as future profitability remains a concern.
Market Sentiment
The increase in Microbix's stock price could signal a growing interest in the biotech sector, especially as the company engages with industry experts and updates its investor presentations. However, potential investors should stay cautious given the company's financial challenges.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
